Virtu Financial LLC Mersana Therapeutics, Inc. Transaction History

Virtu Financial LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $23,092 - $85,179	21,785 New	21,785 $28,000
Q3 2022 Nov 07, 2022	BUY	$4.63 - $8.0 $118,162 - $204,168	25,521 New	25,521 $173,000
Q2 2022 Aug 09, 2022	SELL	$2.84 - $5.0 $37,698 - $66,370	-13,274 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$3.74 - $6.63 $49,644 - $88,006	13,274 New	13,274 $53,000
Q4 2021 Feb 17, 2022	SELL	$5.48 - $9.86 $102,897 - $185,141	-18,777 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$8.56 - $14.47 $160,731 - $271,703	18,777 New	18,777 $177,000
Q1 2021 May 19, 2021	SELL	$15.31 - $26.52 $350,415 - $606,989	-22,888 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$16.84 - $27.59 $385,433 - $631,479	22,888 New	22,888 $609,000

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $52.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.